Basilea Pharmaceutica Ltd. (BSLN)

Overview

Basilea Pharmaceutica AG is a pioneering commercial-stage biopharmaceutical company that dedicates its efforts to fulfilling unmet medical demands in the specialized fields of oncology and anti-infectives. The establishment, founded in the year 2000, is strategically headquartered in Allschwil, Switzerland. It has cemented its reputation by developing innovative pharmaceutical products aimed at tackling challenging health concerns, particularly in treating severe infections and cancer. Basilea’s commitment to enhancing patient care and treatment outcomes reflects through its development pipeline and commercialized products, catering to critical therapeutic needs worldwide.

Products and Services

Basilea Pharmaceutica AG's portfolio showcases an impressive range of products, each designed to combat serious health conditions efficiently. Below is an overview of their key products and services:

• Cresemba - An intravenous and oral antifungal medication, Cresemba has been successfully launched to treat invasive aspergillosis and mucormycosis. These are severe fungal infections commonly encountered by immunocompromised individuals, such as cancer or organ transplant patients. Approved in both the United States and the European Union, Cresemba stands as a critical solution in the fight against these life-threatening fungal diseases.
• Zevtera - Focused on addressing bacterial infections, Zevtera serves as an innovative antibiotic for the treatment of community-acquired and hospital-acquired pneumonia. Beyond its efficacy in tackling pneumonia, Zevtera is also approved for the treatment of acute bacterial skin and skin structure infections and Staphylococcus aureus bacteremia. Its broad application potential makes it a valuable asset in managing severe bacterial diseases.
• Fosmanogepix - Currently in Phase II clinical trials, Fosmanogepix represents Basilea’s commitment to expanding its antifungal arsenal. This promising antifungal drug targets Candidemia, a bloodstream infection caused by Candida species. With its state-of-the-art mechanism of action, Fosmanogepix aims to provide a novel therapeutic option for patients suffering from this challenging and often resistant infection.